Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Condylomata Acuminata 3Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Keratosis, Actinic 2Head and Neck Neoplasms 2Breast Neoplasms 2Wounds and Injuries 1Virus Diseases 1Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Squamous Intraepithelial Lesions 1Skin Neoplasms 1Sexually Transmitted Diseases 1Parapsoriasis 1Papillomavirus Infections 1Non-Muscle Invasive Bladder Neoplasms 1Non-Melanoma Skin Cancers 1Lymphoma, Follicular 1Keratosis, Seborrheic 1Hypogonadism 1Hemangioma, Cavernous 1Hemangioma 1Fatigue 1Exanthema 1Eunuchism 1Dermatitis, Contact 1

Interventions

Gemcitabine 6Trastuzumab 4Carboplatin 3pembrolizumab 2Pemetrexed 2Paclitaxel 2Cisplatin 2vinflunine 1tucatinib 1relatlimab 1palbociclib 1niraparib 1motexafin gadolinium 1montanide ISA 51 1flt3 ligand protein 1enfortumab vedotin 1cabozantinib 1atezolizumab 1apatorsen 1abemaciclib 1Zoledronic Acid 1Urinary Diversion 1Therapeutics 1Thalidomide 1Sunitinib 1Radiosurgery 1Nivolumab 1Mitomycin 1MART-1 Antigen 1Immunoglobulins, Intravenous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urologic Neoplasms × Gels × Clear all
NCT02307487 2017-06-16

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

UroGen Pharma Ltd.

Phase 2 Completed
14 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡